Healthtech sells patents ($5M) and World Reach units ($25M); CEO replaced

Healthtech Solutions, Inc./UT

Sold one patent and four applications to Papyrus Therapeutic for $5M cash; perpetual license back to HTWC for wound care products.
Sold 100% of World Reach Holdings to Papyrus Distribution for $25M base price, with $10M deferred via promissory notes.
CEO and director Jelena Olmstead resigned effective June 6, 2025; James Pesoli appointed CEO.
Transactions involved related parties (Pesoli and Olmstead had conflicting interests; approved by uninterested directors).
Patent license grants HTWC perpetual, worldwide, non-exclusive right to manufacture DermaBind products with monthly royalties.

item 1.01item 2.01item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

James Pesoli

Chief Executive Officer

Healthtech Solutions, Inc./UT

Effective: 2025-06-06
Filed: Jun 13, 2025 23:59 UTC

James Pesoli, the president and a director of the Company, was appointed as the chief executive officer of the Company.

Departed

Jelena Olmstead

Chief Executive Officer and Director

Healthtech Solutions, Inc./UT

Effective: 2025-06-06
Successor: James Pesoli
Filed: Jun 13, 2025 23:59 UTC

Jelena Olmstead, who served as chief executive officer and a director of the Company, resigned as a director, officer and employee of the Company and HTWC.

Source: SEC EDGAR

accession 0001829126-25-004487

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.